Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Relypsa Inc (NASDAQ:RLYP)

33.11
Delayed Data
As of Jul 31
 -0.63 / -1.87%
Today’s Change
17.60
Today|||52-Week Range
42.26
+7.50%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$1.4B

Company Description

Relypsa, Inc. operates as a clinical-stage pharmaceutical company focused on the development and commercialization of non absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. Its products include patiromer, a non-absorbed for the treatment of hyperkalemia and RLY6002, polymer drug discovery technology. The company was founded on October 29, 2007 and is headquartered in Redwood City, CA.

Contact Information

Relypsa, Inc.
100 Cardinal Way
Redwood City California 94063
P:
Investor Relations:

Employees

Shareholders

Other institutional49.68%
Mutual fund holders35.31%
Individual stakeholders34.51%

Top Executives

John A. OrwinPresident, Chief Executive Officer & Director
Wilhelm StahlSenior Vice President-Pharmaceutical Operations
Kristine McClintock BallChief Financial Officer & Senior Vice President
Lance BermanChief Medical Officer & Senior Vice President
Stephen D. HarrisonChief Scientific Officer & Senior Vice President